Bio-Rad - Preparing for a Stress-free QC Audit

Sartorius and Repligen Corporation introduce integrated system with Biostat STR and XCell ATF for upstream process intensification

The life science group Sartorius and Repligen Corporation have launched of an integrated bioreactor system that incorporates Repligen XCell ATF upstream intensification technology into Sartorius’ Biostat STR bioreactor, simplifying intensified seed train and N perfusion implementation for biopharmaceuti­cal manufacturers. The Biostat STR now contains a fully compatible embedded XCell ATF hardware and software module offering predefined advanced control recipes with integrated Process Analytical Technology (PAT). This system gives users a streamlined way to control cell growth and improve cell retention in perfusion processes without using a separate cell retention control tower.

The life science group Sartorius and Repligen Corporation have launched of an integrated bioreactor system that incorporates Repligen XCell ATF upstream intensification technology into Sartorius’ Biostat STR bioreactor, simplifying intensified seed train and N perfusion implementation for biopharmaceuti­cal manufacturers. The Biostat STR now contains a fully compatible embedded XCell ATF hardware and software module offering predefined advanced control recipes with integrated Process Analytical Technology (PAT). This system gives users a streamlined way to control cell growth and improve cell retention in perfusion processes without using a separate cell retention control tower.

In addition, customers can better utilize facility space with a reduced equipment footprint from the incorporation of the XCell Controller hardware and software in the Biobrain automation platform, creating a single point of control for 50 L – 2000 L upstream intensification processes. The single, integrated controller provides easy integration into Supervisory Control and Data Acquisition (SCADA) and Distributed Control Systems (DCS).

“The market introduction of this integrated bioreactor–intensification system created in partnership with Repligen further reinforces Sartorius’ commitment to being an innovator in process intensification and demonstrates our expertise in upstream processing technologies,” said Mario Becker, Head of Product Group Bioreactor Technologies, Sartorius. “Ultimately, our goal is to help customers bring more therapeutics to patients faster, and this launch advances our journey along that path to enable continuous manufacturing.”

Customers are now able to easily purchase the integrated system from Sartorius, with available pretested and predefined configurations, resulting in faster delivery times than engineered-to-order solutions.

For more information, visit: https://www.sartorius.com/en/products/fermentation-bioreactors/single-use-bioreactors/biostat-str

Digital issue: Please click here for more information

Biostat STR